natgillin/translations-raw huggingface dataset:
For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of still water or apple juice. 
Bolnikom, ki ne morejo pogoltniti filmsko obloženih tablet, lahko tablete raztopimo v kozarcu navadne vode ali jabolčnega soka.
Imatinib Actavis will only be prescribed to you by a doctor with experience in medicines to treat blood cancers or solid tumours. 
Zdravilo Imatinib Actavis vam lahko predpiše samo zdravnik, ki ima izkušnje z zdravili za zdravljenje krvnih rakov ali solidnih tumorjev.
Considering the combined concentration of imatinib and the metabolite and the maximum daily milk intake by infants, the total exposure would be expected to be low (~10% of a therapeutic dose). 
Pri seštevku koncentracij imatiniba in njegovega presnovka je pri največji zaužiti količini materinega mleka na dan mogoče pričakovati nizko skupno izpostavljenost dojenčka zdravilu in presnovku (~10 % terapevtskega odmerka).
Imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr-Abl tyrosine kinase at the in vitro, cellular and in vivo levels. 
Imatinib je zaviralec protein-tirozin-kinaze, ki močno zavira Bcr-Abl tirozin-kinazo na in vitro, celični in in vivo ravni.
When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females. 
14 dni pred parjenjem in nato ves čas do 6. dne brejosti, ni bilo nikakršnega učinka na parjenje ali na število brejih samic.
The effect of bodyweight on the clearance of imatinib is such that for a patient weighing 50 kg the mean clearance is expected to be 8.5 L/h, while for a patient weighing 100 kg the clearance will rise to 11.8 L/h. 
Vpliv telesne mase na očistek imatiniba je takšen, da je pri bolniku, ki tehta 50 kg, pričakovani povprečni očistek 8,5 L/h, pri bolniku, ki tehta 100 kg, pa se očistek poveča na 11,8 L/h.
Imatinib treatment induces a rapid response in newly diagnosed paediatric CML patients with a CHR of 78% after 8 weeks of therapy. 
Zdravljenje z zdravilom Imatinib Actavis povzroči hiter odziv pri na novo diagnosticiranih pediatričnih bolnikih s popolnim hematološkim odzivom 78 % po 8 tednih zdravljenja.
The no observed effect level (NOEL) for both the maternal animals and the F1 generation was 15 mg/kg/day (one quarter of the maximum human dose of 800 mg). 
Odmerek brez opaženega učinka (NOEL - no observed effect level) tako na samice-matere kot na generacijo F1 je bil 15 mg/kg/dan (ena četrtina največjega odmerka za človeka, ki je 800 mg).
Patients were treated with imatinib 340 mg/m2/day, with no interruptions in the absence of dose limiting toxicity. 
Bolniki so bili zdravljeni z odmerki imatiniba 340 mg/m2/dan brez prekinitev; toksičnih učinkov, zaradi katerih bi zmanjševali odmerjanje, ni bilo.
HES/CEL (at dose 400 mg) 
HES/CEL (pri odmerku 400 mg)
Imatinib Actavis is a medicine containing an active substance called imatinib. 
Imatinib Actavis je zdravilo, ki vsebuje zdravilno učinkovino z imenom imatinib.
Imatinib Actavis is indicated for - the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. 
Zdravilo Imatinib Actavis je indicirano za - zdravljenje odraslih bolnikov z neresektabilnim protuberantnim dermatofibrosarkomom (DFSP dermatofibrosarcoma protuberans) in tistih odraslih bolnikov z rekurentnim in/ali metastatskim DFSP, ki niso primerni za operacijo.
Non-haematological adverse reactions 
Hematološke neželene reakcije
Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase (TK), as well as several receptor TKs: Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta). 
Imatinib je majhna molekula in je zaviralec protein-tirozin-kinaze, ki močno zavira aktivnost Bcr-Abl tirozin-kinaze, pa tudi nekaj receptorskih tirozin-kinaz: pri receptorju Kit, ki je receptor za dejavnik matičnih celic (SCF - stem cell factor), ki ga kodira protoonkogen c-Kit, pri receptorjih za diskoidinsko domeno (DDR1 in DDR2), pri receptorju za kolonije stimulirajoči faktor (CSF-1R) in pri receptorjih za rastni faktor iz trombocitov alfa in beta (PDGFR-alfa in PDGFR-beta - platelet-derived growth factor receptors).
Patients were treated at doses of imatinib of 260 mg/m2/day (n=5), 340 mg/m2/day (n=9), 440 mg/m2/day (n=7) and 570 mg/m2/day (n=5). 
Bolniki so bili zdravljeni z odmerki imatiniba 260 mg/m2/dan (n=5), 340 mg/m2/dan (n=9), 440 mg/m2/dan (n=7) in 570 mg/m2/dan (n=5).
Treatment duration: In the only clinical trial performed up to now, treatment with imatinib was continued until disease progression (see section 5.1). 
Trajanje zdravljenja: V edinem do zdaj izvedenem kliničnem preskušanju so zdravljenje z zdravilom Imatinib Actavis nadaljevali do napredovanja bolezni (glejte poglavje 5.1).
In patients with impaired renal function, imatinib plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha-acid glycoprotein (AGP), an imatinib-binding protein, in these patients. 
Kaže, da je pri bolnikih z okvarjenim delovanjem ledvic izpostavljenost imatinibu v plazmi višja kot pri bolnikih z normalnim delovanjem ledvic, verjetno zato, ker je pri teh bolnikih zvišana vrednost alfa kislega glikoproteina (AGP-alpha-acid glycoprotein) v plazmi, proteina, ki veže imatinib.
When given with a high-fat meal, the rate of absorption of imatinib was minimally reduced (11% decrease in Cmax and prolongation of tmax by 1.5 h), with a small reduction in AUC (7.4%) compared to fasting conditions. 
Če so imanitib dajali z zelo mastnim obrokom, se je obseg njegove absorpcije minimalno zmanjšal (Cmax se je zmanjšala za 11 %, tmax pa se je podaljšal za 1,5 ure), AUC pa se je v primerjavi z razmerami na tešče malo zmanjšala (7,4 %).
In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade 3/4 GI bleeds (3 patients), intra-tumoural bleeds (3 patients) or both (1 patient). 
V študiji pri bolnikih z neresektabilnimi in/ali metastatskimi GIST je imelo 7 (5 %) bolnikov gastrointestinalne krvavitve CTC stopnje 3/4 (3 bolniki), intratumorske krvavitve (3 bolniki) ali obe vrsti krvavitev (1 bolnik).
Imatinib and the N-demethyl metabolite together accounted for about 65% of the circulating radioactivity (AUC(0-48h)). 
Imatinib in N-demetilirani presnovek sta skupaj prispevala okrog 65 % radioaktivnosti v krvi (AUC(0
Close monitoring of growth in children under imatinib treatment is recommended (see section 4.8). 
Pri otrocih, ki prejemajo imatinib, je priporočeno natančno spremljanje njihove rasti (glejte poglavje 4.8).
If a severe non-haematological adverse reaction develops with imatinib use, treatment must be withheld until the event has resolved. 
Nehematološke neželene reakcije Če med uporabo imatiniba nastopi huda nehematološka neželena reakcija, je treba zdravljenje prekiniti, dokler reakcija ne izzveni.
Myelodysplastic/myeloproliferative diseases with PDGFR gene re-arrangements could be associated with high eosinophil levels. 
Mielodisplastične/mieloproliferativne bolezni s preureditvijo gena za PDGFR so lahko povezane z velikimi koncentracijami eozinofilcev.
Patients with mild, moderate or severe liver dysfunction should be given the minimum recommended dose of 400 mg daily. 
Bolniki z blago, zmerno ali hudo disfunkcijo jeter naj prejmejo najmanjši priporočeni odmerek 400 mg na dan.
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). 
Izkušenj z uporabo zdravila Imatinib Actavis pri bolnikih MDS/MPD v povezavi s preureditvijo genov za PDGFR je malo (glejte poglavje 5.1).
One blister contains 10 capsules. 
En pretisni omot vsebuje 10 kapsul.
Experience with imatinib in this indication is very limited and is based on haematological and cytogenetic response rates. 
Za to indikacijo je izkušenj z zdravilom Imatinib Actavis zelo malo in temeljijo na hematološki in citogenetični odzivnosti.
The European Medicines Agency has waived the obligation to submit the results of studies with imatinib in all subsets of the paediatric population in Philadelphia chromosome (bcr-abl translocation)positive chronic myeloid leukaemia (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z imatinibom za vse skupine pediatrične populacije s kronično mieloično levkemijo s prisotnim kromosomom Philadelphia (s translokacijo bcr-abl) (za podatke o uporabi pri pediatrični populaciji glejte poglavje
No new target organs were identified in the rat juvenile development toxicology study (day 10 to 70 postpartum) with respect to the known target organs in adult rats. 
V študiji toksičnih učinkov na razvoj mladih podgan (od 10. do 70. dne po rojstvu) niso odkrili novih tarčnih organov v primerjavi z znanimi tarčnimi organi pri odraslih podganah.
In rats, hyperplasia of the transitional epithelium in the renal papilla and in the urinary bladder was observed at doses ≥ 6 mg/kg in the 13-week study, without changes in serum or urinary parameters. 
Pri podganah so v 13-tedenski študiji pri odmerkih ≥ 6 mg/kg našli hiperplazijo prehodnega epitela v ledvični papili in v sečnem mehurju, brez sprememb serumskih ali urinskih parametrov.
For patients (children) unable to swallow the capsules, their content may be diluted in a glass of either still water or apple juice. 
Bolnikom (otrokom), ki ne morejo pogoltniti kapsul, lahko njihovo vsebino razredčimo v kozarcu navadne vode ali jabolčnega soka.
What you need to know before you take Imatinib Actavis 
Kaj morate vedeti, preden boste vzeli zdravilo Imatinib Actavis
One blister contains either 8 or 10 capsules. 
En pretisni omot vsebije 8 ali 10 kapsul.
Hepatitis B reactivation* 
Neznana reaktivacija hepatitisa B*
There was more myelosuppression seen in CML patients than in GIST, which is probably due to the underlying disease. 
Pri bolnikih s KML je bila izrazitejša mielosupresija kot pri bolnikih z GIST, kar je verjetno posledica osnovne bolezni.
9/L) were observed in 3.6% and < 1% of patients, respectively. 
3,6 % oziroma < 1 % bolnikov.
Imatinib Actavis is also a treatment for children with CML. 
Zdravilo Imatinib Actavis je namenjeno tudi zdravljenju otrok s KML.
In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. 
Pri odraslih in pediatričnih bolnikih temelji učinkovitost imatiniba na celotni hematološki in citogenetični odzivnosti in preživetju brez napredovanja bolezni pri KML, na hematološki in citogenetični odzivnosti pri Ph+ ALL in MDS/MPD, na hematološki odzivnosti pri HES/CEL ter na objektivni odzivnosti odraslih bolnikov z neresektabilnimi in/ali metastatskim DFSP.
If you are unable to swallow the tablets, you can dissolve them in a glass of still or mineral water or apple juice: - Use about 50 ml for each 100 mg tablet. 
Če ne morete pogoltniti tablet, jih lahko raztopite v kozarcu navadne ali mineralne vode ali jabolčnega soka: - Za vsako tableto po 100 mg potrebujete približno 50 ml vode.
1800 to 3200 mg (as high as 3200 mg daily for 6 days): Weakness, myalgia, increased creatine phosphokinase, increased bilirubin, gastrointestinal pain. 
Odmerki od 1800 mg do 3200 mg (tudi do 3200 mg na dan 6 dni): oslabelost, mialgija, zvišana kreatin-kinaza, zvišan bilirubin, bolečine v prebavilih.
In the study in patients with unresectable and/or metastatic GIST, both gastrointestinal and intra-tumoural haemorrhages were reported (see section 4.8). 
V študiji pri bolnikih z neresektabilnimi in/ali metastatskimi GIST so poročali tako o gastrointestinalnih kot o intratumorskih krvavitvah (glejte poglavje 4.8).
Pretreatment with multiple doses of rifampicin 600 mg followed by a single 400 mg dose of imatinib resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment. 
Predzdravljenje z večkratnimi odmerki rifampicina 600 mg, ki jim je sledil en 400-miligramski odmerek imatiniba, je povzročilo zmanjšanje Cmax oziroma AUC(0-∞) za vsaj 54 % oziroma 74 % zadevnih vrednosti brez zdravljenja z rifampicinom.
There have been post-marketing reports of spontaneous abortions and infant congenital anomalies from women who have taken imatinib. 
V obdobju trženja zdravila so poročali o spontanih splavih in prirojenih nepravilnostih pri dojenčkih mater, ki so med nosečnostjo prejemale imatinib.
Based on pooled population pharmacokinetic analysis in paediatric patients with haematological disorders (CML, Ph+ALL, or other haematological disorders treated with imatinib), clearance of imatinib increases with increasing body surface area (BSA). 
Po rezultatih populacijske farmakokinetične analize združenih podatkov pediatričnih bolnikov s hematološkimi boleznimi (s KML, s Ph+ALL ali s katero od drugih hematoloških bolezni, pri katerih se pri zdravljenju uporablja imatinib), se očistek imatiniba zvišuje z večanjem telesne površine.
Elimination Based on the recovery of compound(s) after an oral 14C-labelled dose of imatinib, approximately 81% 
Na podlagi izločenih spojin po peroralnem odmerku imatiniba, označenega s 14C, se je približno 81 %
When needed, discontinuation of imatinib treatment may be considered. 
Če je treba, velja razmisliti o prekinitvi zdravljenja z zdravilom Imatinib Actavis.
Treatment can be given as a once daily dose or alternatively the daily dose may be split into two administrations - one in the morning and one in the evening. 
Zdravljenje lahko poteka v obliki enega samega odmerka na dan ali pa dnevni odmerek razdelimo na dva - enega zjutraj in enega zvečer.
Pack containing either 24, 48, 60, 96, 120 or 180 capsules 
Škatle, ki vsebujejo 24, 48, 60, 96, 120 ali 180 kapsul.
In patients with hypereosinophilic syndrome (HES) with occult infiltration of HES cells within the myocardium, isolated cases of cardiogenic shock/left ventricular dysfunction have been associated with HES cell degranulation upon the initiation of imatinib therapy. 
Pri bolnikih s hipereozinofilnim sindromom (HES) z okultno infiltracijo HES celic v srčni mišici je v posameznih primerih v povezavi z degranulacijo HES celic ob uvedbi zdravljenja z imatinibom prišlo do kardiogenega šoka/disfunkcije levega prekata.
- Cough, having difficulty breathing or painful breathing (signs of lung problems). 
- kašelj, težave z dihanjem ali bolečine pri dihanju (znaki težav s pljuči),
Based on population pharmacokinetic analysis in CML patients, there was a small effect of age on the volume of distribution (12% increase in patients > 65 years old). 
Na podlagi analize populacijske farmakokinetike pri bolnikih s KML so ugotovili majhen učinek starosti na volumen porazdelitve (12-odstotno povečanje pri bolnikih, starejših od 65 let), vendar ta sprememba ni klinično pomembna.
- If you are a woman who is pregnant or might get pregnant and are trying to open the capsules, you should handle the contents with caution in order to avoid skin-eye contact or inhalation. 
- Če ste noseči ali bi lahko zanosili, ravnajte pri odpiranju kapsule z vsebino pazljivo in se izogibajte stiku zdravila z očmi preko rok ali vdihavanju zdravila.
Imatinib Actavis may do the same to some other medicines. 
Zdravilo Imatinib Actavis lahko enako vpliva na nekatera druga zdravila.
4 Flushing was most common in GIST patients and bleeding (haematoma, haemorrhage) was most common in patients with GIST and with transformed CML (CML-AP and CML-BC). 
4 Navali rdečice so bili najpogostejši pri bolnikih z GIST, krvavitve (hematomi in krvavitve) pa so bile najpogostejše pri bolnikih z GIST in s transformacijo KML (KML-AP in KML-BC).
10 film-coated tablets 30 film-coated tablets 60 film-coated tablets 90 film-coated tablets 
10 filmsko obloženih tablet 30 filmsko obloženih tablet 60 filmsko obloženih tablet 90 filmsko obloženih tablet
10 film-coated tablets 20 film-coated tablets 30 film-coated tablets 60 film-coated tablets 90 film-coated tablets 120 film-coated tablets 180 film-coated tablets 
10 filmsko obloženih tablet 20 filmsko obloženih tablet 30 filmsko obloženih tablet 60 filmsko obloženih tablet 90 filmsko obloženih tablet 120 filmsko obloženih tablet 180 filmsko obloženih tablet
At clinically relevant concentrations of imatinib, binding to plasma proteins was approximately 95% on the basis of in vitro experiments, mostly to albumin and alpha-acid-glycoprotein, with little binding to lipoprotein. 
Pri klinično pomembnih koncentracijah imatiniba je bila vezava na plazemske beljakovine na podlagi poskusov in vitro približno 95-odstotna, večina imatiniba se je vezala na albumine in kisli glikoprotein alfa, malo pa na lipoproteine.
In this study, 14 patients with HES/CEL were treated with 100 mg to 1,000 mg of imatinib daily. 
V tej študiji je 14 bolnikov s HES/CEL prejemalo od 100 mg do 1.000 mg zdravila Imatinib Actavis na dan.
One 3-year-old male exposed to a single dose of 400 mg experienced vomiting, diarrhoea and anorexia and another 3-year-old male exposed to a single dose of 980 mg experienced decreased white blood cell count and diarrhoea. 
Pri enem 3 leta starem dečku, ki je bil izpostavljen enkratnemu odmerku 400 mg, je prišlo do bruhanja, driske in anoreksije, pri drugem 3 leta starem dečku, ki je bil izpostavljen enkratnemu odmerku 980 mg, pa je prišlo do zmanjšane koncentracije levkocitov in driske.
- Patients who are concerned about their fertility while taking Imatinib Actavis are advised to consult with their doctor. 
- Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z zdravilom Imatinib Actavis, naj se posvetujejo s svojim zdravnikom.
Maximal plasma concentrations of imatinib in patients are 2-4 μmol/L, consequently an inhibition of CYP2D6 and/or CYP3A4/5-mediated metabolism of co-administered drugs is possible. 
Največje koncentracije imatiniba v plazmi bolnikov so 2-4 μmol/L, zato je možna inhibicija sočasno uporabljanih zdravil, katerih presnova poteka preko CYP2D6 in/ali CYP3A4/5.
Positive genotoxic effects were obtained for imatinib in an in vitro mammalian cell assay (Chinese hamster ovary) for clastogenicity (chromosome aberration) in the presence of metabolic activation. 
Pozitivne genotoksične učinke so dobili za imatinib pri in vitro testiranju na sesalskih celicah (jajčnik kitajskega hrčka) za klastogenost (kromosomska aberacija) v prisotnosti presnovne aktivacije.
Patients concerned about their fertility on imatinib treatment should consult with their physician. 
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z imatinibom, naj se posvetujejo s svojim zdravnikom.
Since studies in animals have shown reproductive toxicity, and the potential risk for the human foetus is unknown, women of child-bearing potential who open capsules should be advised to handle the contents with caution and avoid skin-eye contact or inhalation (see section 4.6). 
Ker so študije pri živalih pokazale toksičnost za razmnoževanje, potencialno tveganje za človeški plod pa je neznano, je treba ženskam v rodni dobi svetovati, naj pri odpiranju kapsul pazljivo ravnajo z vsebino in se izogibajo stiku zdravila z očmi preko rok ali vdihavanju zdravila (glejte poglavje 4.6).
(≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), 
Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki
If elevations in bilirubin > 3 x institutional upper limit of normal (IULN) or in liver transaminases > 5 x IULN occur, imatinib should be withheld until bilirubin levels have returned to < 1.5 x IULN and transaminase levels to < 2.5 x IULN. 
Če pride do zvišanja bilirubina na > 3-kratno zgornjo mejo normalnih vrednosti, specifično za ustanovo, (IULN-institutional upper limit of normal) ali zvišanja jetrnih aminotransferaz na > 5-kratno IULN, je treba zdravljenje z imatinibom prekiniti, dokler se koncentracija bilirubina ne vrne na < 1,5-kratno IULN oziroma koncentracija aminotransferaz na < 2,5-kratno IULN.
BCR-ABL tyrosine kinase inhibitors (TKIs) have been associated with thrombotic microangiopathy (TMA), including individual case reports for Imatinib Actavis (see section 4.8). 
Zaviralce tirozin kinaze BCR-ABL povezujejo z razvojem trombotične mikroangiopatije, o posameznih primerih so poročali tudi pri uporabi zdravila Imatinib Actavis (glejte poglavje 4.8).
Imatinib may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.). 
Imatinib lahko zveča plazemske koncentracije drugih zdravil, ki jih presnavlja CYP3A4 (na primer triazolo-benzodiazepinov, dihidropiridinskih zaviralcev kalcijevih kanalčkov, nekaterih zaviralcev reduktaze HMG-CoA, tj. statinov, itn.).
If you are unable to swallow the tablets, you can dissolve them in a glass of still or mineral water or apple juice: Use about 200 ml for each 400 mg tablet. 
Če ne morete pogoltniti tablet, jih lahko raztopite v kozarcu navadne ali mineralne vode ali jabolčnega soka: - Za vsako tableto po 400 mg potrebujete približno 200 ml vode.
6+7 Abdominal pain and gastrointestinal haemorrhage were most commonly observed in GIST patients. 
6+7 Bolečine v trebuhu in krvavitev iz prebavil so najpogosteje opažali pri bolnikih z GIST.
Do not stop taking Imatinib Actavis unless your doctor tells you to. 
Ne prenehajte jemati zdravila Imatinib Actavis, razen če vam tako naroči zdravnik.
Continuous daily exposure to imatinib early in the course of treatment in combination with chemotherapy in cohort 5-patients (n=50) improved the 4-year event-free survival (EFS) compared to historical controls (n=120), who received standard chemotherapy without imatinib (69.6% vs. 31.6%, respectively). 
Pri bolnikih v 5. kohorti (n = 50) je neprekinjena vsakodnevna izpostavljenost imatinibu zgodaj v poteku zdravljenja v kombinaciji s kemoterapijo povečala delež bolnikov s 4-letnim preživetjem brez dogodkov (EFS - event-free survival) v primerjavi z zgodovinskimi kontrolami (n = 120), kjer so bolniki prejeli standardno kemoterapijo brez imatiniba (69,6 % v primerjavi z 31,6 %).
Grade 3 and 4 neutropenia was seen in 7.5% and 2.7% of patients, respectively, and grade 3 thrombocytopenia in 0.7% of patients. 
Nevtropenijo 3. in 4. stopnje so odkrili pri 7,5 % oziroma 2,7 % bolnikov, trombocitopenijo 3. stopnje pa pri 0,7 % bolnikov.
Imatinib Actavis can help you to fight this condition. 
Zdravilo Imatinib Actavis vam lahko pomaga pri premagovanju te bolezni.
Imatinib Actavis may cause your body to retain water (severe fluid retention). 
Zaradi zdravila Imatinib Actavis lahko telo zadržuje vodo (lahko pride do hudega zastajanja tekočine).
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p<0.001; OS p<0.0001) in two studies (AJP01 and AUS01). 
V dveh študijah (AJP01 in AUS01) sta preživetje brez bolezni (DSF - disease-free survival) in celokupno preživetje (OS - overall survival) konstantno presegala 1 leto in sta bila daljša kot pri zgodovinskih kontrolah (DFS p<0,001; OS p<0,0001).
If either is abnormal, follow-up with a cardiology specialist and the prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with imatinib should be considered at the initiation of therapy. 
primeru nenormalnega izvida katere od teh preiskav je potrebno razmisliti o kontrolnem pregledu pri kardiologu in sočasni profilaktični uporabi steroidov s sistemskim delovanjem (1-2 mg/kg) ob uvedbi zdravljenja z imatinibom, v obdobju enega do dveh tednov.